PB 98 of 2020

National Health (Continued Dispensing) Amendment Determination 2020 (No. 1)

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health make the following determination.

Dated     28 September 2020

THEA CONNOLLY  

Contents

1 Name

2 Commencement

3 Authority

4  Schedule

Schedule 1—Amendments 2

National Health (Continued Dispensing) Determination 2012 2

1  Name

(1)  This instrument is the National Health (Continued Dispensing) Amendment Determination 2020 (No. 1).

(2)  This instrument may also be cited as PB 98 of 2020.

2  Commencement

(1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 89A(3) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Continued Dispensing) Determination 2012

[1]           Part 1, Section 1.03, definition for ‘PSA Guidelines’

substitute: PSA Guidelines means the document titled Guidelines for the Continued Dispensing of eligible prescribed medicines by pharmacists, issued by the Pharmaceutical Society of Australia.

[2]           Schedule 1, Part 1, entry for Levonorgestrel with Ethinyloestradiol

omit from the column headed “Listed Drug”: Levonorgestrel with Ethinyloestradiol  substitute: Levonorgestrel with ethinylestradiol

[3]           Schedule 1, Part 1, entry for Norethisterone with Ethinyloestradiol

(a)    omit from the column headed “Listed Drug”: Norethisterone with Ethinyloestradiol  substitute: Norethisterone with ethinylestradiol

(b)    omit:

[4]           Schedule 1, Part 2, entry for Fluvastatin

omit: